You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Primary peritoneal carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 19, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Biopsy
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +3 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 8, 2022

Patients With Low Grade Ovarian or Peritoneal Tumors

Recruiting
  • Low Grade Ovarian Serous Adenocarcinoma
  • +5 more
  • Biospecimen Collection
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma Trial in Rochester (Biopsy,

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +14 more
  • Biopsy
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 28, 2023

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Trial in Beijing (Niraparib)

Recruiting
  • Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Nov 15, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 17, 2022

Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Tumor Trial in Rochester

Active, not recruiting
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +22 more
  • Laboratory Biomarker Analysis
  • Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
  • Rochester, Minnesota
    Mayo Clinic
Oct 7, 2022

Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Tumor, Advanced Ovarian Carcinoma Trial in Bethesda, Boston (Biopsy,

Recruiting
  • Advanced Fallopian Tube Carcinoma
  • +21 more
  • Biopsy
  • +2 more
  • Bethesda, Maryland
  • +2 more
Jan 25, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +6 more
  • Biopsy
  • Pegylated SN-38 Conjugate PLX038
  • Rochester, Minnesota
    Mayo Clinic
Jul 19, 2022

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 12, 2023

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7

Active, not recruiting
  • Stage III Fallopian Tube Cancer AJCC v7
  • +14 more
  • Minneapolis, Minnesota
  • +1 more
Jan 27, 2023

Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III Trial in China

Recruiting
  • Epithelial Ovarian Carcinoma Stage III
  • +5 more
  • nab-paclitaxel combined with carboplatin
  • Guangzhou, Guangdong, China
  • +10 more
Feb 19, 2023

High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial (Sovilnesib)

Not yet recruiting
  • High Grade Serous Adenocarcinoma of Ovary
  • +3 more
  • (no location specified)
Oct 13, 2023

Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma Trial in Italy (carboplatin and paclitaxel followed by surgery)

Active, not recruiting
  • Ovarian Cancer
  • +2 more
  • carboplatin and paclitaxel followed by surgery
  • Bologna, Italy
  • +4 more
Dec 28, 2022

Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma Trial in Portland (Wee1

Not yet recruiting
  • Advanced Fallopian Tube Carcinoma
  • +10 more
  • Wee1 Inhibitor ZN-c3
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jan 25, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Philadelphia (MOv19-BBz CAR T cells, Alpha Folate

Recruiting
  • Ovarian Cancer
  • +2 more
  • MOv19-BBz CAR T cells
  • Alpha Folate Receptor expression test
  • Philadelphia, Pennsylvania
    University of Pennsylvania Health System
Sep 12, 2022

Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer Trial (Pegylated Liposomal Doxorubicin +

Not yet recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • Pegylated Liposomal Doxorubicin + SL-172154
  • Mirvetuximab + SL-172154
  • (no location specified)
Jul 29, 2022

Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Epithelial Ovarian Cancer Trial in Baltimore (procedure, drug, other)

Recruiting
  • Stage III Ovarian Cancer
  • +6 more
  • Cytoreductive Surgery (CRS)
  • +6 more
  • Baltimore, Maryland
    Mercy Medical Center
Aug 30, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Australia (ATX-101 + Carboplatin + Pegylated

Recruiting
  • Ovarian Cancer
  • +3 more
  • ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
  • Blacktown, New South Wales, Australia
  • +5 more
Nov 9, 2022